Literature DB >> 21506900

Antimicrobial treatment of anaerobic infections.

Itzhak Brook1.   

Abstract

INTRODUCTION: Anaerobes are the most predominant components of normal human skin and mucous membrane bacterial flora and are, therefore, a common cause of endogenous bacterial infections. Because of their fastidious nature, they are difficult to isolate from infectious sites and are often overlooked. Anaerobic infections can occur at all body sites, including the central nervous system, oral cavity, head and neck, chest, abdomen, pelvis, skin and soft tissues. AREAS COVERED: This up-to-date review describes the antimicrobials available for the treatment of anaerobic infections and the advantages in using them according to the site of infection and expected antimicrobial susceptibility. EXPERT OPINION: Treatment of anaerobic infection is complicated by the slow growth of these organisms, their polymicrobial nature and the growing resistance of anaerobes to antimicrobials. Antimicrobial therapy is often the only therapy required, or it is an important adjunct to a surgical approach. Because anaerobes generally are recovered mixed with aerobic organisms, the choice of appropriate antimicrobial should provide adequate coverage of both types of pathogen. The most effective antimicrobials against anaerobes are: metronidazole, the carbapenems, chloramphenicol, the combinations of a penicillin and a beta-lactamase inhibitor, and tigecycline.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21506900     DOI: 10.1517/14656566.2011.576672

Source DB:  PubMed          Journal:  Expert Opin Pharmacother        ISSN: 1465-6566            Impact factor:   3.889


  8 in total

1.  How antibiotics kill bacteria: new models needed?

Authors:  Gerard D Wright; Deborah T Hung; John D Helmann
Journal:  Nat Med       Date:  2013-05       Impact factor: 53.440

2.  Ceftaroline plus avibactam demonstrates bactericidal activity against pathogenic anaerobic bacteria in a one-compartment in vitro pharmacokinetic/pharmacodynamic model.

Authors:  Brian J Werth; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2013-11-11       Impact factor: 5.191

Review 3.  An Updated Review on the Synthesis and Antibacterial Activity of Molecular Hybrids and Conjugates Bearing Imidazole Moiety.

Authors:  Renzo Rossi; Maurizio Ciofalo
Journal:  Molecules       Date:  2020-11-04       Impact factor: 4.411

4.  Expanded therapeutic potential in activity space of next-generation 5-nitroimidazole antimicrobials with broad structural diversity.

Authors:  Yukiko Miyamoto; Jaroslaw Kalisiak; Keith Korthals; Tineke Lauwaet; Dae Young Cheung; Ricardo Lozano; Eduardo R Cobo; Peter Upcroft; Jacqueline A Upcroft; Douglas E Berg; Frances D Gillin; Valery V Fokin; K Barry Sharpless; Lars Eckmann
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-07       Impact factor: 11.205

5.  Anaerobic bacteria growth in the presence of cathelicidin LL-37 and selected ceragenins delivered as magnetic nanoparticles cargo.

Authors:  Bonita Durnaś; Ewelina Piktel; Marzena Wątek; Tomasz Wollny; Stanisław Góźdź; Jolanta Smok-Kalwat; Katarzyna Niemirowicz; Paul B Savage; Robert Bucki
Journal:  BMC Microbiol       Date:  2017-07-26       Impact factor: 3.605

6.  Biochemical and structural characterization of Haemophilus influenzae nitroreductase in metabolizing nitroimidazoles.

Authors:  Dake Liu; Thisuri N Wanniarachchi; Guangde Jiang; Gustavo Seabra; Shugeng Cao; Steven D Bruner; Yousong Ding
Journal:  RSC Chem Biol       Date:  2022-02-16

7.  Increasing Fusobacterium infections with Fusobacterium varium, an emerging pathogen.

Authors:  Se Ju Lee; Yae Jee Baek; Jin Nam Kim; Ki Hyun Lee; Eun Hwa Lee; Joon Sup Yeom; Jun Yong Choi; Nam Su Ku; Jin Young Ahn; Jung Ho Kim; Su Jin Jeong
Journal:  PLoS One       Date:  2022-04-14       Impact factor: 3.752

Review 8.  Identification and Antimicrobial Susceptibility Testing of Anaerobic Bacteria: Rubik's Cube of Clinical Microbiology?

Authors:  Márió Gajdács; Gabriella Spengler; Edit Urbán
Journal:  Antibiotics (Basel)       Date:  2017-11-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.